BRISTOL-MYERS SQUIBB CO (BMY) Stock Price, Forecast & Analysis
NYSE:BMY • US1101221083
BMY Key Statistics, Chart & Performance
The current stock price of BMY is 60.66 USD. In the past month the price increased by 10.41%. In the past year, price increased by 8.65%.
BMY Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BMY. When comparing the yearly performance of all stocks, BMY is one of the better performing stocks in the market, outperforming 76.46% of all stocks.
BMY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BMY. BMY scores excellent on profitability, but there are some minor concerns on its financial health.
BMY Financial Highlights
Over the last trailing twelve months BMY reported a non-GAAP Earnings per Share(EPS) of 6.15. The EPS increased by 439.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.57% | ||
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| Debt/Equity | 2.41 |
BMY Forecast & Estimates
34 analysts have analysed BMY and the average price target is 58.05 USD. This implies a price decrease of -4.3% is expected in the next year compared to the current price of 60.66.
For the next year, analysts expect an EPS growth of -1.05% and a revenue growth -7.97% for BMY
BMY Ownership
BMY Latest News, Press Relases and Analysis
BMY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.6 | 302.459B | ||
| PFE | PFIZER INC | 8.87 | 152.718B | ||
| ZTS | ZOETIS INC | 18.75 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.29 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BMY
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016 US
CEO: Giovanni Caforio
Employees: 34100
Phone: 13026587581
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What does BRISTOL-MYERS SQUIBB CO do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the current price of BMY stock?
The current stock price of BMY is 60.66 USD. The price increased by 0.6% in the last trading session.
Does BMY stock pay dividends?
BRISTOL-MYERS SQUIBB CO (BMY) has a dividend yield of 4.21%. The yearly dividend amount is currently 2.42.
What is the ChartMill technical and fundamental rating of BMY stock?
BMY has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (BMY) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy BMY stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BMY.
What is the market capitalization of BMY stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a market capitalization of 123.49B USD. This makes BMY a Large Cap stock.